Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
DR. REDDYS LAB ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
DR. REDDYS LAB Mar-23 |
ADCOCK INGRAM Jun-14 |
DR. REDDYS LAB/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 4,656 | 314 | - | |
Low | Rs | 3,788 | 226 | - | |
Sales per share (Unadj.) | Rs | 1,481.4 | 93.4 | - | |
Earnings per share (Unadj.) | Rs | 270.7 | -23.5 | - | |
Cash flow per share (Unadj.) | Rs | 345.7 | -19.5 | - | |
Dividends per share (Unadj.) | Rs | 40.00 | 0 | - | |
Avg Dividend yield | % | 0.9 | 0 | - | |
Book value per share (Unadj.) | Rs | 1,389.6 | 73.3 | - | |
Shares outstanding (eoy) | m | 166.53 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 2.8 | 2.9 | 98.5% | |
Avg P/E ratio | x | 15.6 | -11.5 | -135.8% | |
P/CF ratio (eoy) | x | 12.2 | -13.9 | -88.1% | |
Price / Book Value ratio | x | 3.0 | 3.7 | 82.4% | |
Dividend payout | % | 14.8 | 0 | - | |
Avg Mkt Cap | Rs m | 703,039 | 45,603 | 1,541.7% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 46,466 | 2,862 | 1,623.5% | |
Avg. sales/employee | Rs Th | 0 | 3,671.4 | - | |
Avg. wages/employee | Rs Th | 0 | 666.7 | - | |
Avg. net profit/employee | Rs Th | 0 | -925.1 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 246,697 | 15,761 | 1,565.2% | |
Other income | Rs m | 10,555 | 110 | 9,563.1% | |
Total revenues | Rs m | 257,252 | 15,872 | 1,620.8% | |
Gross profit | Rs m | 63,860 | -2,731 | -2,338.1% | |
Depreciation | Rs m | 12,502 | 680 | 1,837.9% | |
Interest | Rs m | 1,428 | 427 | 334.5% | |
Profit before tax | Rs m | 60,485 | -3,728 | -1,622.4% | |
Minority Interest | Rs m | 0 | -10 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 15,412 | 233 | 6,615.9% | |
Profit after tax | Rs m | 45,073 | -3,971 | -1,134.9% | |
Gross profit margin | % | 25.9 | -17.3 | -149.4% | |
Effective tax rate | % | 25.5 | -6.2 | -407.8% | |
Net profit margin | % | 18.3 | -25.2 | -72.5% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 203,161 | 11,544 | 1,759.9% | |
Current liabilities | Rs m | 85,721 | 6,495 | 1,319.8% | |
Net working cap to sales | % | 47.6 | 32.0 | 148.6% | |
Current ratio | x | 2.4 | 1.8 | 133.3% | |
Inventory Days | Days | 79 | 111 | 71.4% | |
Debtors Days | Days | 107 | 124 | 86.5% | |
Net fixed assets | Rs m | 112,638 | 6,729 | 1,674.0% | |
Share capital | Rs m | 833 | 73 | 1,138.3% | |
Net worth | Rs m | 231,404 | 12,371 | 1,870.6% | |
Long term debt | Rs m | 1,278 | 4,347 | 29.4% | |
Total assets | Rs m | 315,799 | 23,369 | 1,351.3% | |
Interest coverage | x | 43.4 | -7.7 | -560.7% | |
Debt to equity ratio | x | 0 | 0.4 | 1.6% | |
Sales to assets ratio | x | 0.8 | 0.7 | 115.8% | |
Return on assets | % | 14.7 | -15.2 | -97.1% | |
Return on equity | % | 19.5 | -32.1 | -60.7% | |
Return on capital | % | 26.6 | -19.8 | -134.3% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 58,875 | 1,345 | 4,376.2% | |
From Investments | Rs m | -41,373 | -413 | 10,015.7% | |
From Financial Activity | Rs m | -26,861 | 3,945 | -680.8% | |
Net Cashflow | Rs m | -9,073 | 4,878 | -186.0% |
Compare DR. REDDYS LAB With: ACTAVIS (US) MYLAN (US) TEVA PHARMA (Israel)
Compare DR. REDDYS LAB With: HEMO ORGANIC AARTI PHARMALABS VAISHALI PHARMA BAL PHARMA HINDUSTAN BIOSCIE
Indian share markets continued the momentum as the session progressed and ended the higher.